Researchers sought to better understand the risk for recurrence and precipitants for relapse in anterior uveitis, potentially allowing clinicians to better provide a prognosis and disease course with ...
Please provide your email address to receive an email when new articles are posted on . At the end of March, Wu and colleagues published online in JAMA Ophthalmology the first report on 12 cases of ...
LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to ...
Background and aim Juvenile idiopathic arthritis-associated uveitis (JIAU) is a potentially blinding condition beginning in ...
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
Conjunctival hyperemia in the right eye (Panel A) and left eye (Panel B) 8 days after the onset of systemic symptoms is shown. Also shown are keratic precipitates and grade 2+ inflammatory cells (on a ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback